Skip to main content

Praxis Precision Medicines, Inc.

PRAX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001689548

No open-market purchases or sales by Praxis Precision Medicines, Inc. insiders were filed in the last 90 days; 309 institutions reported holding it in 13F filings for Q2 2026, worth $11.3B in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Praxis Precision Medicines, Inc. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of PRAX: Q1 2025 compared with Q2 2025
MeasureQ1 2025Q2 2025Change
Holders150144−6
Shares23.5M24.2M+699.7K (+3.0%)
Value$889.3M$1.02B+$126.3M (+14.2%)

New holders (25)

Institutions that held Praxis Precision Medicines, Inc. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to PRAX in Q2 2025
InstitutionSharesValue% of portfolio
Logos Global Management LP225,000$9.46M1.26%
Vivo Capital, LLC167,600$7.05M0.72%
Exome Asset Management LLC59,002$2.48M2.05%
StemPoint Capital LP32,255$1.36M0.44%
Capital Fund Management S.A.24,292$1.02M0.01%
Prelude Capital Management, LLC19,900$836.8K0.08%
AQR Capital Management LLC14,580$613.1K0.00%
Brevan Howard Capital Management LP8,503$357.6K0.00%
Creative Planning6,495$273.1K0.00%
Susquehanna Portfolio Strategies, LLC5,750$241.8K0.01%
Cerity Partners LLC5,611$235.9K0.00%
Virtu Financial LLC5,058$213.0K0.01%
Jefferies Financial Group Inc.5,000$210.3K0.00%
Maven Securities LTD5,000$210.3K0.05%
Voya Investment Management LLC4,919$206.8K0.00%
Toronto Dominion Bank3,100$130.4K0.00%
Skopos Labs, Inc.298$12.5K0.00%
Russell Investments Group, Ltd.249$10.5K0.00%
Caitong International Asset Management Co., Ltd219$9.21K0.01%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.133$6.00K0.00%
Larson Financial Group LLC38$1.60K0.00%
SRS Capital Advisors, Inc.23$9680.00%
Twin Peaks Wealth Advisors, LLC1$480.00%
National Bank of Canada1$420.00%
Essential Partners LLC1$420.00%

Sold out (31)

Institutions that held Praxis Precision Medicines, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.